226 related articles for article (PubMed ID: 24091100)
1. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
Paioli A; Luksch R; Fagioli F; Tamburini A; Cesari M; Palmerini E; Abate ME; Marchesi E; Balladelli A; Pratelli L; Ferrari S
J Chemother; 2014 Feb; 26(1):49-56. PubMed ID: 24091100
[TBL] [Abstract][Full Text] [Related]
2. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
4. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study.
Ferrari S; Palmerini E; Alberghini M; Staals E; Mercuri M; Barbieri E; Longhi A; Cantero L; Cesari M; Abate M; Balladelli A; Picci P; Bacci G
Tumori; 2010; 96(2):213-8. PubMed ID: 20572576
[TBL] [Abstract][Full Text] [Related]
5. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Kushner BH; Meyers PA
J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Brennan B; Kirton L; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Fenwick N; Strauss S; Moroz V; Whelan J; Wheatley K
Lancet; 2022 Oct; 400(10362):1513-1521. PubMed ID: 36522207
[TBL] [Abstract][Full Text] [Related]
7. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
[TBL] [Abstract][Full Text] [Related]
8. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
Juergens C; Weston C; Lewis I; Whelan J; Paulussen M; Oberlin O; Michon J; Zoubek A; Juergens H; Craft A
Pediatr Blood Cancer; 2006 Jul; 47(1):22-9. PubMed ID: 16572419
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
Le Deley MC; Paulussen M; Lewis I; Brennan B; Ranft A; Whelan J; Le Teuff G; Michon J; Ladenstein R; Marec-Bérard P; van den Berg H; Hjorth L; Wheatley K; Judson I; Juergens H; Craft A; Oberlin O; Dirksen U
J Clin Oncol; 2014 Aug; 32(23):2440-8. PubMed ID: 24982464
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
Brunetto AL; Castillo LA; Petrilli AS; Macedo CD; Boldrini E; Costa C; Almeida MT; Kirst D; Rodriguez-Galindo C; Pereira WV; Watanabe FM; Pizza M; Benites E; Morais V; Gadelha A; Nakasato A; Abujamra AL; Gregianin LJ;
Pediatr Blood Cancer; 2015 Oct; 62(10):1747-53. PubMed ID: 25917418
[TBL] [Abstract][Full Text] [Related]
12. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
Anderton J; Moroz V; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Kaiser S; Fernández-Pinto M; Fenwick N; Evans A; Strauss S; Whelan J; Wheatley K; Brennan B
Trials; 2020 Jan; 21(1):96. PubMed ID: 31952545
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Womer RB; West DC; Krailo MD; Dickman PS; Pawel BR; Grier HE; Marcus K; Sailer S; Healey JH; Dormans JP; Weiss AR
J Clin Oncol; 2012 Nov; 30(33):4148-54. PubMed ID: 23091096
[TBL] [Abstract][Full Text] [Related]
14. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
15. Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
Mascarenhas L; Felgenhauer JL; Bond MC; Villaluna D; Femino JD; Laack NN; Ranganathan S; Meyer J; Womer RB; Gorlick R; Krailo MD; Marina N
Pediatr Blood Cancer; 2016 Mar; 63(3):493-8. PubMed ID: 26579879
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
Marina NM; Pappo AS; Parham DM; Cain AM; Rao BN; Poquette CA; Pratt CB; Greenwald C; Meyer WH
J Clin Oncol; 1999 Jan; 17(1):180-90. PubMed ID: 10458232
[TBL] [Abstract][Full Text] [Related]
17. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
18. RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
Thomson B; Hawkins D; Felgenhauer J; Radich J
Bone Marrow Transplant; 1999 Sep; 24(5):527-33. PubMed ID: 10482938
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
Meyer WH; Kun L; Marina N; Roberson P; Parham D; Rao B; Fletcher B; Pratt CB
J Clin Oncol; 1992 Nov; 10(11):1737-42. PubMed ID: 1403056
[TBL] [Abstract][Full Text] [Related]
20. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]